Form 4: Cyclacel Director Reduces Stake After Warrant Exchange

A Cyclacel Pharmaceuticals director and 10% owner exchanged warrants for common stock but significantly reduced their overall common share holdings.

Summary

• Yap Kim Choy, a Director and 10% Owner of Cyclacel Pharmaceuticals, Inc. (CYCC), executed transactions on September 4, 2025.
• The reporting person exchanged 186,465 Series C Common Stock Purchase Warrants for an equal number of Common Stock shares.
• These warrants had an exercise price of $10.2 per share and an expiration date of June 20, 2030.
• Concurrently, 404,465 shares of Common Stock were disposed of on the same date.
• Following these transactions, Yap Kim Choy beneficially owns 31,535 Series C Common Stock Warrants.

Sentiment

Score: 4

Explanation: While the warrant exchange converts a derivative into direct equity, the simultaneous disposition of a larger number of common shares by a director and 10% owner suggests a negative sentiment or liquidity event for the insider, which can be concerning for the market.

Positives

• The conversion of 186,465 warrants into common stock by a director increases their direct equity stake for those specific shares, aligning interests more closely with common shareholders.

Negatives

• The net disposition of 218,000 common shares (404,465 disposed minus 186,465 acquired via warrant exchange) by a director and 10% owner represents a significant reduction in their direct equity exposure.
• Such a substantial insider sale can be interpreted by the market as a lack of confidence in the company's near-term prospects or valuation.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders may interpret the significant net disposition of common stock by a director and 10% owner as a negative signal regarding the company's future prospects or valuation.

Key Dates

Recommendation

The significant net disposition of 218,000 common shares by Yap Kim Choy, a director and 10% owner, on the same day as a warrant exchange, is a strong negative signal. This type of insider selling often indicates a lack of confidence from a highly informed party or a need for personal liquidity, which can precede periods of underperformance for the stock. Investors should view this as a cautionary sign.

Keywords

Cyclacel Pharmaceuticals, CYCC, Form 4, Insider Trading, Beneficial Ownership, Warrant Exchange, Common Stock, Director Transaction, Yap Kim Choy